Bombesin receptors regulate EGFR transactivation in cancer
Main Article Content
Bombesin (BB)-like peptides are autocrine growth factors for small cell lung cancer (SCLC), a neuroendocrine tumor. BB-like peptides are present in and secreted from SCLC cells, where they bind to cell surfact G protein coupled receptors (GPCR). When the BB2R is activated it interacts with a G-protein (Gq) causing signal transduction mechanisms which lead to increased cellular proliferation. The growth of SCLC is inhibited by BB2R antagonists. In Non-SCLC (NSCLC) cells, but not SCLC cells, the receptor tyrosine kinase (RTK) for epidermal growth factor (EGF) predominates. Addition of NMB to NSCLC cells, causes tyrosine phosphorylation of the EGFR through a process called transactivation. The EGFR transactivation caused by NMB addition to NSCLC cells is inhibited by BB1R antagonists and EGFR tyrosine kinase inhibitors (TKI) such as gefitinib or erlotinib. BB1R antagonists are synergistic with gefitinib at inhibiting NSCLC growth. The BB1R may regulate the growth of NSCLC, an epithelial tumor, in an EGFR-dependent manner.
How to Cite
MOODY, Terry. Bombesin receptors regulate EGFR transactivation in cancer. Medical Research Archives, [S.l.], n. 3, june 2015. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/216>. Date accessed: 29 mar. 2023.
bombesin, EGF receptors, transactivation, tyrosine kinase inhibitors, bombesin receptor antagonists, lung cancer
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.